A review published in Diabetes Therapy on March 28 suggests that GLP-1 receptor agonists and DPP-4 inhibitors, already widely prescribed for type 2 diabetes, may also protect peripheral nerves from diabetic damage.
The evidence is largely experimental plus limited clinical data, and the authors call for larger trials before practice changes.
Diabetic peripheral neuropathy (DPN) is the most frequent microvascular complication of diabetes mellitus, and current treatment guidelines focus primarily on glucose control and pain alleviation, the review notes. That leaves a gap: no widely available therapy has been shown to reverse the underlying nerve damage itself.
The new analysis, led by researchers at Democritus University of Thrace in Alexandroupolis, Greece, together with colleagues at the Clinical Centre of Vojvodina in Novi Sad, Serbia, examined whether two of the most commonly used antidiabetic drug classes could fill it.
“Limited but promising” clinical data have shown improved somatosensory-evoked potentials and vibration perception threshold, as well as restored excitability and nerve size parameters, the authors write.
GLP-1 agonists and DPP-4 inhibitors show early nerve-protective signals
- Two drug classes you or a family member may already take for diabetes — GLP-1 receptor agonists (the injectable “incretin” drugs) and DPP-4 inhibitor tablets — showed signs of helping damaged nerves in laboratory and small clinical studies.
- This does not mean either class treats neuropathy today. No regulator has approved them for that purpose, and the clinical evidence reviewed is described by its own authors as limited.
- Pain relief remains the standard of care for symptomatic diabetic neuropathy; anyone considering a change should discuss it with their diabetes specialist.
Why nerve damage has resisted treatment
DPN can reduce protective sensation, lead to neuropathic pain and impair health-related quality of life, the review states. Because current approaches largely target symptoms, researchers have been searching for agents that act on the disease process itself — the progressive loss of nerve fibres in the skin and limbs.
The two drug classes in question work through the incretin system. GLP-1 and glucose-dependent insulinotropic peptide (GIP) are gut hormones released after eating that stimulate insulin secretion; this “incretin effect” is seriously impaired in type 2 diabetes. DPP-4 inhibitors work by blocking the enzyme that degrades GLP-1, while GLP-1 receptor agonists mimic the hormone directly, the review explains.
What the laboratory evidence shows
The strongest signals come from experimental work. Immunohistochemical data — laboratory staining techniques that reveal structures inside tissue — indicate that agents in both categories promote neurite outgrowth (the sprouting of new nerve fibre extensions), ion conduction, neuronal survival and Schwann cell function. Schwann cells are the support cells that insulate peripheral nerves and keep them functioning.
Intra-epidermal nerve fibre density, a direct measure of the small nerve fibres that branch into the skin, has been reported to increase with treatment by either class. Electrophysiological studies — recordings of how fast electrical signals travel along nerves — showed a diverse, but mostly beneficial, effect on motor and sensory nerve conduction velocity.
Animal behavioural tests pointed the same way. Clinical-style assessments such as muscular grip or paw jumping control, which resemble neuropathic symptoms, confirmed the advantageous effect of both drug classes, according to the review.
Where the human evidence stands
The clinical data are thinner. Studies reviewed by the authors reported improved somatosensory-evoked potentials (recordings of how the spinal cord and brain respond to sensory signals), improved vibration perception threshold, and restored nerve excitability and nerve size parameters. The review also cites early data that were not promising, noting that more recent evidence has sparked new interest in this therapeutic approach.
That mixed trajectory matters for interpretation. The authors searched Scopus, PubMed/MEDLINE and Google Scholar without time restriction, and their conclusion is deliberately restrained: further clinical studies are required before these findings translate into practice. A related review indexed on PubMed reaches the same position, encouraging use only after “further large-scale studies.”
Commercial stakes and author industry ties disclosed
Interest in this question is not academic curiosity alone. GLP-1 receptor agonists are among the most commercially successful drugs in medicine, and any nerve-protective effect would add a major indication to drugs already prescribed for glucose control, obesity and cardiovascular risk reduction.
Readers should weigh the funding and disclosure picture carefully. The competing-interest statement accompanying the review lists extensive industry ties among the authors: G.S. has received speaker fees from Procter and Gamble Health, Viatris and Eli Lilly; D.S. has received speaker fees from Wörwag Pharma and Grünenthal, research support to their institution from Withings, Abbott Laboratories, Tandem Diabetes and P&G Health, and serves on the executive committee of the Novo Nordisk UK Research Foundation; D.Z. has received consultant fees from AstraZeneca, Bayer, Clexio, Grünenthal, GSK, Novaremed, Nevro, Novo Nordisk, P&G, Syqe, TrigoCare, Viatris and Wörwag Pharma, plus speaker fees from AstraZeneca, Daiichi Sankyo, Eva, Grünenthal, Nevro, Sanofi, Viatris and Wörwag Pharma; and S.T. has received consultant and speaker fees from Wörwag Pharma, Grünenthal, Nevro, Viatris, Merz, P&G Health and Medtronics, with institutional research support from Withings, Viatris and P&G Health.
Several of these companies market GLP-1 receptor agonists or DPP-4 inhibitors directly.
None of this invalidates the review — disclosure statements exist precisely so readers can judge for themselves — but it is a relevant fact for a field where the drugs under study are also the authors’ funders’ products.
What the findings could mean for regulators and patients
The review is based on previously conducted studies and contains no new trials with human participants or animals, the authors state. That matters for how regulators treat it: agencies such as the FDA in the United States and the EMA in Europe approve drugs for specific indications based on dedicated randomised trials, not narrative reviews.
Neither agency has approved a GLP-1 receptor agonist or DPP-4 inhibitor for neuropathy, and the American Diabetes Association’s current Standards of Care do not list these agents as disease-modifying treatments for DPN.
For patients, the practical near-term consequence is modest but real. Millions of people with type 2 diabetes already take these drugs for approved reasons, and if ongoing research confirms a nerve-protective effect, that benefit could eventually become part of the rationale for prescribing them — without any new drug needing to be developed. Conversely, if large trials are negative, the field returns to pain management as the ceiling of available therapy.
The open question the authors themselves flag is the exact role of DPP-4 inhibitors and GLP-1 receptor agonists in DPN. Until dedicated large-scale trials answer it, the review’s own framing — limited but promising — is the most defensible summary of where the evidence stands.
Contraindications and specialist guidance for these diabetes drugs
GLP-1 receptor agonists and DPP-4 inhibitors carry established contraindications and side-effect profiles documented in their prescribing information, and none of the sources reviewed here changes that. Patients with a history of pancreatitis, severe gastrointestinal disease, or medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (a contraindication listed for GLP-1 receptor agonists) should not start or adjust these drugs outside specialist guidance.
Symptoms of progressive neuropathy — new numbness, burning pain, weakness, or foot ulcers — warrant prompt assessment by a diabetes care team regardless of medication, because uncontrolled neuropathy is a leading pathway to foot ulceration and amputation. Do not start, stop or switch any glucose-lowering medication based on this review; it reports experimental and preliminary clinical findings, not treatment guidance.
Where the research goes next
The review’s authors state plainly what is needed: further clinical studies to elucidate the exact role of these drugs in diabetic peripheral neuropathy. Large randomised trials with nerve-structure endpoints — such as intra-epidermal nerve fibre density — would be the decisive step. Until such trials report, the therapeutic potential of GLP-1 receptor agonists in diabetic sensorimotor polyneuropathy remains exactly what the paper calls it: potential.
The review’s home institution, Democritus University of Thrace, was established in July 1973 and accepted its first students in the academic year 1974–1975, beginning with departments of Law and Civil Engineering. It takes its name from the ancient Greek philosopher Democritus, who was born in Abdera, Thrace, and is remembered for formulating an atomic theory of matter.
Based in Komotini with campuses across cities including Alexandroupolis, the state-owned university now comprises 10 schools and 28 departments, with more than 25,919 registered undergraduates and over 5,071 postgraduate and PhD students as of 2020.
References
- Panou T, Gouveri E, Popovic DS, et al. “The Therapeutic Potential of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Peripheral Neuropathy.” Diabetes Therapy, 2025. doi.org/10.1007/s13300-025-01712-z
- Nature. “Therapeutic potential of GLP1RAs in diabetic sensorimotor polyneuropathy.”
- American Diabetes Association. Standards of Care in Diabetes — doi.org/10.2337/dc25-S012
- Related review on DPP-4 inhibitors and GLP-1 receptor agonists in diabetic peripheral neuropathy, PMC12085435
- PubMed-indexed literature on incretin-based therapies and neuropathy: pubmed.ncbi.nlm.nih.gov/31456118; pubmed.ncbi.nlm.nih.gov/39651973
Consult a qualified healthcare professional before making any changes to your treatment.